COVID-19患者院内心脏骤停后的死亡率:系统评价与荟萃分析
该系统评价与荟萃分析检索PubMed、EMBASE、Web of Science、bioRxiv和medRxiv至2021年2月8日,纳入10篇文章、共1179例COVID-19患者院内心脏骤停并尝试心肺复苏。估计总体死亡率(院内或30天)为89.9%(95%预测区间83.1%-94.2%;1060/1179例;I²=82%),不可除颤心律发生率为89%(95%预测区间82.8%-93.1%;1022/1205例;I²=85%),自主循环恢复率为32.9%(95%预测区间26%-40.6%;365/1205例;I²=82%),30天良好神经功能生存率为6.3%(95%预测区间4%-9.7%;50/851例;I²=48%)。敏感性分析显示COVID-19患者院内心脏骤停后死亡风险高于非COVID-19患者(OR 2.34;95%CI 1.37-3.99;研究数=3;1215例)。结论指出,尽管三分之一患者可达到自主循环恢复,但近90%在30天内或出院时未能存活。
要点
- COVID-19患者院内心脏骤停并尝试心肺复苏后总体死亡率(院内或30天)为89.9%(95%预测区间83.1%-94.2%;1060/1179例;I²=82%)。
- 不可除颤心律发生率为89%(95%预测区间82.8%-93.1%;1022/1205例;I²=85%)。
- 自主循环恢复率为32.9%(95%预测区间26%-40.6%;365/1205例;I²=82%)。
- 30天良好神经功能生存率为6.3%(95%预测区间4%-9.7%;50/851例;I²=48%)。
- 敏感性分析显示COVID-19患者院内心脏骤停后死亡风险高于非COVID-19患者(OR 2.34;95%CI 1.37-3.99;研究数=3;1215例)。
适用人群与场景
- COVID-19患者发生院内心脏骤停并尝试心肺复苏者(共1179例)。
研究设计与关键结果
- 研究类型为系统评价与荟萃分析,纳入10篇文章,共1179例COVID-19患者院内心脏骤停并尝试心肺复苏。
- 主要终点总体死亡率(院内或30天)为89.9%(95%预测区间83.1%-94.2%;1060/1179例;I²=82%)。
- 不可除颤心律发生率为89%(95%预测区间82.8%-93.1%;1022/1205例;I²=85%)。
- 自主循环恢复率为32.9%(95%预测区间26%-40.6%;365/1205例;I²=82%)。
- 30天良好神经功能生存率为6.3%(95%预测区间4%-9.7%;50/851例;I²=48%)。
- 敏感性分析显示COVID-19患者院内心脏骤停后死亡风险高于非COVID-19患者(OR 2.34;95%CI 1.37-3.99;研究数=3;1215例)。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: To estimate the mortality rate, the rate of return of spontaneous circulation (ROSC) and survival with favorable neurological outcome in patients with COVID-19 after in-hospital cardiac arrest (IHCA) and attempted cardiopulmonary resuscitation (CPR).
METHODS: PubMed, EMBASE, Web of Science, bioRxiv and medRxiv were surveyed up to 8th February 2021 for studies reporting data on mortality of patients with COVID-19 after IHCA. The primary outcome sought was mortality (in-hospital or at 30 days) after IHCA with attempted CPR. Additional outcomes were the overall rate of IHCA, the rate of non-shockable presenting rhythms, the rate of ROSC and the rate of survival with favorable neurological status.
RESULTS: Ten articles were included in the systematic review and meta-analysis, for a total of 1179 COVID-19 patients after IHCA with attempted CPR. The estimated overall mortality rate (in-hospital or at 30 days) was 89.9% (95% Predicted Interval [P.I.] 83.1%-94.2%; 1060/1179 patients; I2 = 82%). The estimated rate of non-shockable presenting rhythms was 89% (95% P.I. 82.8%-93.1%; 1022/1205 patients; I2 = 85%), and the estimated rate of ROSC was 32.9% (95% P.I. 26%-40.6%; 365/1205 patients; I2 = 82%). The estimated overall rate of survival with favorable neurological status at 30 days was 6.3% (95% P.I. 4%-9.7%; 50/851 patients; I2 = 48%). Sensitivity analysis showed that COVID-19 patients had higher risk of death after IHCA than non COVID-19 patients (OR 2.34; 95% C.I. 1.37-3.99; number of studies = 3; 1215 patients).
CONCLUSIONS: Although one of three COVID-19 patients undergoing IHCA may achieve ROSC, almost 90% may not survive at 30 days or to hospital discharge.
参考来源
- Ippolito M, Catalisano G, Marino C, et al. Mortality after in-hospital cardiac arrest in patients with COVID-19: A systematic review and meta-analysis. Resuscitation. 2021. PMID: 33964332. doi:10.1016/j.resuscitation.2021.04.025
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。